I-Mab Reports Results of Olamkicept (TJ301) in P-II Study for Ulcerative Colitis

 I-Mab Reports Results of Olamkicept (TJ301) in P-II Study for Ulcerative Colitis

I-Mab Reports Results of Olamkicept (TJ301) in P-II Study for Ulcerative Colitis

Shots:

  • The P-II study involves assessing Olamkicept (300/600mg, q2w, IV) vs PBO in 91 patients in a ratio (1:1:1) who had active UC with a full Mayo score ≥5, a rectal bleeding subscore ≥1, an endoscopy subscore ≥2, and had an inadequate response with conventional UC therapy
  • The study met its 1EPs & 2EPs, demonstrating higher clinical response rates after 12wks. of treatment with 600mg dose & more patients achieved clinical remission and mucosal healing respectively. Olamkicept was well tolerated with the acceptable safety profile
  • Olamkicept is the only clinical stage selective IL-6 inhibitor that works through the trans-signaling mechanism

Click here to­ read full press release/ article | Ref: PRNewswire | Image: i-Mab

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post